IMMIX BIOPHARMA INC
IMMXNASDAQTrading Snapshot
- Day Range
- $7.63 – $8.10
- 52-Week Range
- $2.85 – $15.10
- Volume (shares)
- 281,404.859
- Avg Volume (shares)
- —
- Shares Outstanding
- 82.9M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -9.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.63
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +39.0%
IMMIX BIOPHARMA INC
IMMX
StockOtter · stockotter.spaceAbout IMMIX BIOPHARMA INC
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present at the 45th Annual J.P. Mo
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
Immix Biopharma (NASDAQ: IMMX) reported updated clinical data for NXC-201, its investigational CAR T-cell therapy for relapsed or refractory light-chain (AL) amyloidosis, and outlined plans for a biologics license applic
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previou
Immix Biopharma (NASDAQ:IMMX) Stock Jumps 4.1% – Should You Buy?
Shares of Immix Biopharma, Inc. (NASDAQ: IMMX - Get Free Report) rose 4.1% during trading on Monday. The stock traded as high as $11.37 and last traded at $11.4250. 314,931 shares changed hands during mid-day trading, a
Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript
Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten